313 related articles for article (PubMed ID: 36973157)
21. Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action.
Ożarowski M; Karpiński TM; Zielińska A; Souto EB; Wielgus K
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919010
[TBL] [Abstract][Full Text] [Related]
22. Cannabidiol or CBD Oil: Help, Hope, and Hype for Psychiatric and Neurologic Conditions.
Newton M; Newton DW
J Am Psychiatr Nurses Assoc; 2020; 26(5):447-457. PubMed ID: 32508204
[No Abstract] [Full Text] [Related]
23. Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents.
Fasinu PS; Phillips S; ElSohly MA; Walker LA
Pharmacotherapy; 2016 Jul; 36(7):781-96. PubMed ID: 27285147
[TBL] [Abstract][Full Text] [Related]
24. Biological bases for a possible effect of cannabidiol in Parkinson's disease.
Ferreira-Junior NC; Campos AC; Guimarães FS; Del-Bel E; Zimmermann PMDR; Brum Junior L; Hallak JE; Crippa JA; Zuardi AW
Braz J Psychiatry; 2020 Apr; 42(2):218-224. PubMed ID: 31314869
[TBL] [Abstract][Full Text] [Related]
25. The Polypharmacological Effects of Cannabidiol.
Castillo-Arellano J; Canseco-Alba A; Cutler SJ; León F
Molecules; 2023 Apr; 28(7):. PubMed ID: 37050032
[TBL] [Abstract][Full Text] [Related]
26. The Pharmacological Basis of Cannabis Therapy for Epilepsy.
Reddy DS; Golub VM
J Pharmacol Exp Ther; 2016 Apr; 357(1):45-55. PubMed ID: 26787773
[TBL] [Abstract][Full Text] [Related]
27. The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law.
Mead A
Epilepsy Behav; 2017 May; 70(Pt B):288-291. PubMed ID: 28169144
[TBL] [Abstract][Full Text] [Related]
28. Cannabinoids, hippocampal excitability and efficacy for the treatment of epilepsy.
Yao I; Stein ES; Maggio N
Pharmacol Ther; 2019 Oct; 202():32-39. PubMed ID: 31176695
[TBL] [Abstract][Full Text] [Related]
29. Biochemical aspects and therapeutic mechanisms of cannabidiol in epilepsy.
Boleti APA; Frihling BEF; E Silva PS; Cardoso PHO; de Moraes LFRN; Rodrigues TAA; Biembengute MEF; Koolen HHF; Migliolo L
Neurosci Biobehav Rev; 2022 Jan; 132():1214-1228. PubMed ID: 33031814
[TBL] [Abstract][Full Text] [Related]
30. [Should ophtalmologists recommend medical cannabis to patients with glaucoma?].
Mouhammad ZA; Kolko M
Ugeskr Laeger; 2018 Jul; 180(29):. PubMed ID: 30020072
[TBL] [Abstract][Full Text] [Related]
31. Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials.
Silvestro S; Mammana S; Cavalli E; Bramanti P; Mazzon E
Molecules; 2019 Apr; 24(8):. PubMed ID: 31013866
[TBL] [Abstract][Full Text] [Related]
32. Constituents of Cannabis Sativa.
Rock EM; Parker LA
Adv Exp Med Biol; 2021; 1264():1-13. PubMed ID: 33332000
[TBL] [Abstract][Full Text] [Related]
33. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.
Elsaid S; Kloiber S; Le Foll B
Prog Mol Biol Transl Sci; 2019; 167():25-75. PubMed ID: 31601406
[TBL] [Abstract][Full Text] [Related]
34. The neuroprotection of cannabidiol against MPP⁺-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson's disease.
Santos NA; Martins NM; Sisti FM; Fernandes LS; Ferreira RS; Queiroz RH; Santos AC
Toxicol In Vitro; 2015 Dec; 30(1 Pt B):231-40. PubMed ID: 26556726
[TBL] [Abstract][Full Text] [Related]
35. Neuroprotective effects of cannabidiol on dopaminergic neurodegeneration and α-synuclein accumulation in C. elegans models of Parkinson's disease.
Muhammad F; Liu Y; Wang N; Zhao L; Zhou Y; Yang H; Li H
Neurotoxicology; 2022 Dec; 93():128-139. PubMed ID: 36108815
[TBL] [Abstract][Full Text] [Related]
36. Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?
Crippa JAS; Hallak JEC; Zuardi AW; Guimarães FS; Tumas V; Dos Santos RG
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):121-133. PubMed ID: 30706171
[TBL] [Abstract][Full Text] [Related]
37. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?
Fernández-Ruiz J; Sagredo O; Pazos MR; García C; Pertwee R; Mechoulam R; Martínez-Orgado J
Br J Clin Pharmacol; 2013 Feb; 75(2):323-33. PubMed ID: 22625422
[TBL] [Abstract][Full Text] [Related]
38. Cannabidiol for Oral Health: A New Promising Therapeutical Tool in Dentistry.
Bellocchio L; Patano A; Inchingolo AD; Inchingolo F; Dipalma G; Isacco CG; de Ruvo E; Rapone B; Mancini A; Lorusso F; Scarano A; Malcangi G; Inchingolo AM
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298644
[TBL] [Abstract][Full Text] [Related]
39. Synthetic and Natural Derivatives of Cannabidiol.
Morales P; Jagerovic N
Adv Exp Med Biol; 2021; 1297():11-25. PubMed ID: 33537934
[TBL] [Abstract][Full Text] [Related]
40. Cannabinoids in epilepsy: clinical efficacy and pharmacological considerations.
Espinosa-Jovel C
Neurologia (Engl Ed); 2023; 38(1):47-53. PubMed ID: 34824031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
